Eli Lilly and Company News - August 2026
Eli Lilly buys Merida for $2.88B, leveraging obesity profits for autoimmune growth
Eli Lilly entered a definitive agreement to acquire Merida Biosciences for up to $2.88 billion. The deal includes an upfront cash payment plus additional...
Lilly's Heart-Shield Label for Mounjaro Closes a Key Gap With Ozempic — But Can a $10 Billion Drug Still Grow Into Its Price?
Shares of Eli Lilly ticked up 0.6% to $1,183.14 Thursday after the FDA approved its blockbuster diabetes drug Mounjaro to reduce the risk of heart attack,...
Eli Lilly's Mounjaro Wins FDA Approval to Lower Heart Risks in Diabetes
The FDA approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes. This...
Eli Lilly, Roche Win FDA Clearance for Alzheimer's Test, Widening Patient Access
The FDA cleared the Elecsys pTau217 blood test co-developed by Eli Lilly and Roche. This test identifies amyloid pathology markers in patients aged 55 and...
Eli Lilly launches Foundayo weight-loss pill in UK, first in Europe
Eli Lilly launched its oral weight-loss and type 2 diabetes pill, Foundayo, in the United Kingdom on Monday. The UK is the first European country to offer the...
Polen Capital Reduces Eli Lilly Stake, Trimming a Top Position
In a notable portfolio adjustment, Polen Capital Management reduced its significant stake in pharmaceutical giant Eli Lilly & Co. (LLY) by 27.08% during the...
Lilly's GLP-1 Bet on Depression Could Open a Massive New Market — But Can Investors Price In a Drug That Won't Exist Until 2028?
Shares of Eli Lilly surged 5.0% to $1,287.23 on August 19, pushing past the previous session's close of $1,225.73, as investors continued to bid up the stock...
🟢 Eli Lilly is trading 5.34% up today after strong Q2 results and higher 2026 guidance
Eli Lilly is trading 5.34% up now at $1291.24, as investors continue rewarding strong second-quarter results and a higher 2026 revenue outlook. -...
🟢 Eli Lilly is trading 4.5% up today after strong Q2 earnings and raised 2026 guidance
Eli Lilly's stock surged 4.5% to $1287.23 today, driven by continued investor enthusiasm following robust second-quarter earnings where revenue jumped 48%. -...
🟢 Eli Lilly is trading 3.1% up today after UK authorizes Foundayo for weight management
Eli Lilly is trading 3.1% up now at $1222.14 after the UK medicines regulator authorized Foundayo for weight management and type 2 diabetes. - The UK is the...
Eli Lilly Wins UK Approval for Foundayo, First Oral GLP-1 in Europe
The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized Eli Lilly’s (LLY) once-daily pill, Foundayo. Foundayo (orforglipron) treats both...
Lilly's Next-Gen Obesity Drug Gets a Head Start — But Can Retatrutide Justify the Stock's Bounce Before FDA Even Weighs In?
Shares of Eli Lilly surged 5.3% to $1,175 in pre-market trading Thursday, snapping a week-long slide, after the company formalized an expanded early-access...
Lilly's Next-Gen Obesity Drug Gets a Head Start — But Can Retatrutide Justify the Stock's Bounce Before FDA Even Weighs In?
Shares of Eli Lilly surged 5.3% to $1,175 in pre-market trading Thursday, snapping a week-long slide, after the company formalized an expanded early-access...
🟢 Eli Lilly is trading 3.33% up today after Q2 revenue and EPS beat, guidance raised
Eli Lilly is trading 3.33% up now at $1190.00 after its August 5, 2026 earnings report exceeded expectations. - Second-quarter revenue was $22.97 billion and...
🟢 Eli Lilly is trading 7.29% up today on a major revenue guidance hike and GLP-1 strength
Eli Lilly is trading 7.29% up at $1,213.51 following its August 5 earnings report, driven by a significant increase in full-year revenue guidance and continued...
Eli Lilly's second quarter revenue surged 48% to $23.0B, prompting a raised FY26 outlook.
Eli Lilly reported second quarter 2026 revenue of $23.0 billion, up 48% year-over-year, and reported EPS of $7.94. The results were driven by strong demand for...
🟢 Eli Lilly surges 5.3% in pre-market on strong Q2 earnings beat and raised full-year guidance
• Eli Lilly is trading 5.3% up at $1,175.00 in pre-market after reporting second-quarter 2026 financial results that exceeded analyst expectations. • The...
Eli Lilly and Company Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Eli Lilly to report Q2 2026 consensus revenue of $20.65 billion and EPS of $6.71, with the current stock price of $1,121.36 sitting below the...